Form 4: Allogene Therapeutics SVP, Finance, Annie Yoshiyama, Reports Stock Sale to Cover Tax Obligations

Annie Yoshiyama, SVP of Finance at Allogene Therapeutics, sold 9,601 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On April 21, 2025, Annie Yoshiyama, SVP of Finance at Allogene Therapeutics, sold 9,601 shares of common stock at a price of $1.41 per share.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• This transaction was mandated by Allogene Therapeutics' equity incentive plan, which requires a 'sell to cover' transaction to satisfy tax obligations.
• Following the transaction, Yoshiyama beneficially owns 130,663 shares of Allogene Therapeutics common stock, which includes 2,274 shares acquired on March 14, 2025, through an employee stock purchase program.

Sentiment

Score: 5

Explanation: The document describes a routine transaction (stock sale to cover taxes) and doesn't contain information that would significantly impact investor sentiment positively or negatively.

Industry Context

Form 4 filings are a routine part of the US stock market and are required by the SEC to ensure transparency when company insiders trade their company's stock. This filing indicates that an officer of the company has sold shares to cover tax obligations, which is a common practice.

Comparison to Industry Standards

• It is common practice for company executives to sell shares to cover tax obligations related to vesting equity awards.
• The 'sell to cover' mechanism is a standard feature in many equity compensation plans across various industries, including biotechnology.
• Comparable companies in the biotechnology sector, such as Gilead Sciences or Amgen, also have executives who routinely file Form 4s for similar transactions.

Stakeholder Impact

• The sale of shares by an executive could have a minor, temporary impact on shareholders due to the increased supply of shares in the market.
• However, since the sale is for tax obligations and not a discretionary trade, the impact is likely to be minimal.

Key Dates

Keywords

Allogene Therapeutics, ALLO, Annie Yoshiyama, Form 4, Stock Sale, Tax Withholding, Equity Incentive Plan, SVP Finance, Beneficial Ownership, Employee Stock Purchase Program